Core Laboratories reported third quarter 2026 revenue of $132.1 million, finishing effectively in-line with estimates despite persistent logistical headwinds in the Middle East. Adjusted EPS of $0.16 narrowly missed the $0.17 consensus. Growth was characterized by a 6% sequential revenue increase driven by recovering international demand in Europe, Asia-Pacific, and Latin America, alongside strong U.S. product sales in the Production Enhancement segment.
Key Highlights
- Reservoir Description revenue reached $84.3 million, exceeding the top end of management's guidance and analysts' $82.5 million estimate.
- Production Enhancement revenue rose to $47.8 million, up 4% sequentially, led by a 14% increase in product sales and growing adoption of proprietary completion technologies.
- Free cash flow was limited to $1.7 million as higher raw material costs for perforating systems and late-quarter activity surges increased working capital requirements.
- The company repurchased 87,873 shares for $1.1 million and maintained its quarterly dividend of $0.01 per share.